ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2019

Friday, May 10, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Three months ended March 31, 2019

Three months ended March 31, 2018

OPERATING EXPENSES

    Research and development

$          1,454

$          1,989

    Financing costs

167

237

    General and administration

1,762

2,180

Total operating expenses

(3,383)

(4,406)

    Gain (loss) on derivative liability

(16)

9

    Other items

(18)

13

Net income (loss) before taxes

(3,417)

(4,384)

Income tax expense

(12)

-

Net income (loss) for the period

$         (3,429)

$         (4,384)

Basic and diluted earnings (loss)per common share

 

$               (0.54)

 

$               (0.83)

Weighted average number of

common shares outstanding

 

6,311,098

 

5,287,605



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store